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Highlights 
 Vitamin D deficiency is common among UK adults with chronic obstructive pulmonary disease 
 Classical environmental determinants of vitamin D status operate in this population 
 Vitamin D status associated with clinical markers of lung function 
 Genetic variation in the vitamin D pathway did not influence vitamin D status or measures of COPD 
severity 
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Abstract 
Vitamin D deficiency is common in patients with chronic obstructive pulmonary disease (COPD), yet a 
comprehensive analysis of environmental and genetic determinants of serum 25-hydroxyvitamin D (25[OH]D) 
concentration in patients with this condition is lacking. We conducted a multi-centre cross-sectional study in 
278 COPD patients aged 41 – 92 years in London, UK. Details of potential environmental determinants of 
vitamin D status and COPD symptom control and severity were collected by questionnaire, and blood samples 
were taken for analysis of serum 25(OH)D concentration and DNA extraction. All participants performed 
spirometry and underwent measurement of weight and height. Quadriceps muscle strength (QS) was 
measured in 134 participants, and sputum induction with enumeration of lower airway eosinophil and 
neutrophil counts was performed for 44 participants. Thirty-seven single nucleotide polymorphisms (SNP) in 
11 genes in the vitamin D pathway (DBP, DHCR7, CYP2R1, CYP27B1, CYP24A1, CYP27A1, CYP3A4, LRP2, CUBN, 
RXRA, and VDR) were typed using Taqman allelic discrimination assays. Linear regression was used to identify 
environmental and genetic factors independently associated with serum 25(OH)D concentration and to 
determine whether vitamin D status or genetic factors independently associated with % predicted forced 
expiratory volume in one second (FEV1), % predicted forced vital capacity (FVC), the ratio of FEV1 to FVC 
(FEV1:FVC), daily inhaled corticosteroid (ICS) dose, respiratory quality of life (QoL), QS, and the percentage of 
eosinophils and neutrophils in induced sputum. Mean serum 25(OH)D concentration was 45.4 nmol/L (SD 
25.3); 171/278 (61.5%) participants were vitamin D deficient (serum 25[OH]D concentration <50 nmol/L). 
Lower vitamin D status was independently associated with higher body mass index (P=0.001), lower socio-
economic position (P=0.037), lack of vitamin D supplement consumption (P<0.001), sampling in Winter or 
Spring (P for trend=0.006) and lack of a recent sunny holiday (P=0.002). Vitamin D deficiency associated with 
reduced % predicted FEV1 (P for trend=0.060) and % predicted FVC (P for trend=0.003), but it did not associate 
with FEV1:FVC, ICS dose, QoL, QS, or the percentage of eosinophils or neutrophils in induced sputum. After 
correction for multiple comparisons testing, genetic variation in the vitamin D pathway was not found to 
associate with serum 25(OH)D concentration or clinical correlates of COPD severity. Vitamin D deficiency was 
common in this group of COPD patients in the UK, and it associated independently with reduced % predicted 
FEV1 and FVC. However, genetic variation in the vitamin D pathway was not associated with vitamin D status 
or severity of COPD. 
 
Key words 
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1. Introduction 
 
Vitamin D deficiency is consistently reported to be more common in patients with chronic obstructive 
pulmonary disease (COPD) than in healthy controls (1-3), and is associated with reduced forced expiratory 
volume in one second (FEV1) (3-8), forced vital capacity (FVC), peak expiratory flow (PEF), respiratory quality of 
life (QoL) (4), increased daily inhaled corticosteroid (ICS) dose and hypoxaemia (8). Findings from studies which 
have investigated the impact of vitamin D status on exercise capacity or skeletal muscle strength are 
conflicting, with some studies reporting inverse associations (6, 9) and others studies reporting null effects (7, 
10). 
In a recent clinical trial we found vitamin D supplementation to significantly reduce risk of COPD exacerbation 
in those who were deficient at baseline (<50 nmol/L) (11). However the determinants of vitamin D deficiency 
in COPD patients, and the clinical correlates of disease severity are not well defined: raised neutrophil and 
eosinophil counts and increased concentrations of inflammatory mediators secreted by these cells have been 
identified in the lower airways during COPD exacerbation (12-14), but to our knowledge, there are no previous 
cross-sectional investigations of serum 25(OH)D concentration and differential white cell counts in induced 
sputum in patients with COPD. Furthermore, environmental and genetic factors which have been shown to 
influence vitamin D status in healthy populations (15, 16) have not yet been well characterised in COPD 
patients, nor have genetic factors which may associate with clinical markers of COPD severity. 
We therefore conducted a cross-sectional analysis to determine the prevalence of vitamin D deficiency in 
COPD patients living in London, UK, and to identify genetic and environmental determinants of vitamin D 
status in this group. We also conducted analyses to explore whether vitamin D status or genetic variation in 
the vitamin D pathway associated with any clinical features of COPD, either independently or in interaction 
with each other. 
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2. Methods 
 
2.1. Participants 
 
Adult patients with a medical record diagnosis of COPD, emphysema or chronic bronchitis were identified by 
database searches at 60 general practices and COPD clinics in 4 Acute National Health Service Trusts in 
London, UK, and invited for screening as previously described (11). The study was approved by East London 
and The City Research Ethics Committee 1 (ref 09/H0703/76) and written informed consent was obtained from 
all participants before enrolment.  
 
2.2. Procedures 
 
Respondents were asked to complete a lifestyle questionnaire detailing age, sex, ethnicity, self-reported 
Fitzpatrick skin-type (17), self-classified socio-economic position (SEP) using the National Statistics – Socio-
Economic Classification (NS-SEC) method (18), number of hours spent outdoors each day, history of recent 
sunny holidays abroad (defined as a trip to any location within a latitude 51
o
 North/South of the equator, 
during the local sunny season, up to 2 months prior to blood draw, for a duration of ≥1 week), smoking 
behaviour and consumption of alcohol and supplemental vitamin D. Respondents also completed the St. 
George’s Respiratory Questionnaire (SGRQ) (19) and underwent a baseline clinical assessment including the 
following: spirometry before and after inhalation of 400 μg salbutamol via a spacer device, performed using a 
MicroLab ML3500 desktop spirometer (CareFusion GmbH, Hoechberg, Germany) with calculation of % 
predicted FVC and FEV1 values according to American Thoracic Society (ATS) / European Respiratory Society 
(ERS) recommendations (20, 21); height measurement (using a Seca 220 Telescopic Measuring Rod, Seca, 
Hamburg, Germany); and weight measurement (using Marsden MMPS-250 column scales, Marsden, 
Rotherham, UK). A blood sample was collected for subsequent DNA extraction and determination of serum 
concentration of total 25(OH)D and parathyroid hormone (PTH). One sub-set of 134 participants underwent 
measurement of leg quadriceps strength using a Nicholas manual muscle tester (Lafayette Instruments, US). 
Another sub-set of 44 participants underwent sputum induction with hypertonic saline, and their samples 
were processed to make cytospin slides according to methods described by Pizzichini et al (22). Participants’ 
COPD severity was categorised according to Global Initiative on Obstructive Lung Disease (GOLD) stages: 
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mild/GOLD stage 1 (FEV1 ≥80%), moderate/GOLD stage 2 (FEV1 50-79%), severe/GOLD stage 3 (FEV1 30-49%), 
and very severe/GOLD stage 4 (FEV1 <30%).  
 
2.3. Single nucleotide polymorphism panel selection 
 
A literature search of the PubMed database was performed to identify SNP previously shown to associate with 
serum 25(OH)D concentration and/or non-skeletal disease, described here (23). We identified 55 such SNP in 
11 genes in the vitamin D pathway. Based on linkage disequilibrium (LD) relationships between these SNP, we 
selected 6 tagging SNP (tSNP) (24), using a r
2
 threshold of 0.8, which reduced the number of genotyped SNP to 
37. 
 
2.4. Laboratory analyses 
 
Serum concentrations of 25(OH)D2 and 25(OH)D3 were determined by isotope-dilution liquid chromatography–
tandem mass spectrometry (14) in the Department of Clinical Biochemistry at Homerton Hospital, and 
summed to give total serum 25(OH)D concentration. This laboratory participates in the international vitamin D 
external quality assurance scheme (www.deqas.org/). PTH concentrations were determined using an Architect 
ci8200 analyser (Abbott Diagnostics, Chicago, IL, USA). DNA was extracted from whole blood using a salting-
out method (15) on the Biomek FX robot (Beckman Coulter), quantified using the Nanodrop 
spectrophotometer and normalised to 5ng/µl.  10ng DNA were used as template for 2 µl TaqMan assays 
(Applied Biosystems, Foster City, CA, USA) performed on the ABI 7900HT platform in 384-well format and 
analysed with Autocaller software as previously described (25). Typing for two SNP failed (rs6127118, CYP24A1 
and rs11574010, VDR). 
 
2.5. Statistical analyses 
 
Using STATA 12 we performed unpaired Student’s T tests or one-way ANOVA tests on normally distributed 
dependent variables (serum 25[OH]D concentration, % predicted FEV1, % predicted FVC, QS, SGRQ score, and 
% neutrophils in induced sputum) and Mann-Whitney or Kruskal-Wallis tests on non-normally distributed 
dependent variables (FEV1:FVC, ICS dose, and % eosinophils in induced sputum) to identify correlates of serum 
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25(OH)D concentration, vitamin D pathway SNP, and clinical features of COPD severity on univariate analysis. 
All dependent variables were continuous. Non-normally distributed dependent variables had positively skewed 
distributions, and were transformed to their natural logarithms for multivariate analyses. All factors with a 
minimum of 5 participants at each level were then fitted in a multivariate model to give adjusted regression 
coefficients, along with a 95% confidence interval and a P value for pairwise association in variables with 2 
categories, or a P value for trend for variables with ≥3 categories. For the analysis of association between 
vitamin D pathway SNP and clinical correlates of COPD severity, a P value for the interaction between SNP 
genotype and baseline vitamin D status was also calculated. In the case of log-transformed dependent 
variables, the anti-logs of adjusted regression coefficients are presented. Genetic analyses were adjusted for 
all putative environmental determinants of serum 25(OH)D concentration investigated (for 15 SNP previously 
found to associate with vitamin D status), or clinical correlates of COPD severity (for 35 SNP previously found 
to associate with vitamin D status and/or non-skeletal disease outcomes). Multiple comparison testing was 
then applied using the Benjamini & Hochberg method with a false discovery rate (FDR) of 5% (16). All 
environmental and genetic independent variables were classified as categorical variables. All SNP were 
analysed under an additive model. 
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3. Results 
 
3.1. Study population 
 
A total of 278 adult COPD patients were enrolled in the study between 11
th
 September 2009 and 12
th
 April 
2012. All consented to undergo clinical measurements and to donate blood samples for quantification of 
serum 25(OH)D and PTH concentration; 277/278 consented to donate a blood sample for DNA storage and 
genotyping. Participant characteristics are presented in Table 1. Age range was 40.8 to 91.9 years, with a mean 
of 66.4 years (SD 9.5). Most participants (60.8%) were male. The majority of participants (94.2%) classified 
their ethnic origin as being White; 1.8% classified their ethnic origin as Asian/Asian British; 0.7% as Black/Black 
British; 1.8% as being of mixed ethnicity; and 1.4% preferred not to report their ethnicity. Participants’ COPD 
was managed exclusively in primary care in 202/278 (72.7%). Mean serum 25(OH)D concentration for all 
participants was 45.3 nmol/L (SD 25.4). Sixty-one participants (21.9%) had serum 25(OH)D concentration <25 
nmol/L; 110 (39.6%) had serum 25(OH)D concentration in the range 25-49.9 nmol/L; 74 (26.6%) had serum 
25(OH)D concentration in the range 50-74.9 nmol/L; and 33 (11.9%) had serum 25(OH)D concentration ≥75 
nmol/L. 
 
3.2. Environmental determinants of serum 25(OH)D concentration 
 
Environmental determinants of vitamin D status are presented in Table 2. Multiple linear regression analysis 
showed the following factors to independently associate with lower serum 25(OH)D concentration: higher BMI 
(adjusted mean difference of -10.1 nmol/L for <25 kg/m
2 
vs.
 
≥25 kg/m
2
; 95% CI -16.2 to -4.0 nmol/L; P=0.001); 
lower SEP (adjusted mean difference of -6.6 nmol/L for lower vs. higher classes; 95% CI -12.8 to -0.4 nmol/L; 
P=0.037); lack of vitamin D supplement consumption (adjusted mean difference of -12.4 nmol/L for those 
taking no supplement vs. those taking any supplement; 95% CI -19.6 to -5.2 nmol/L; P<0.001); sampling in 
January – March vs. July-September (adjusted mean difference -14.0 nmol/L; 95% CI -22.3 to -5.7 nmol/L; P for 
trend = 0.006); and lack of a recent sunny holiday abroad (adjusted mean difference of -20.2 nmol/L for those 
without vs. with such a holiday; 95% CI -32.7 to -7.6 nmol/L; P=0.002).  
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3.3. Genetic determinants of serum 25(OH)D concentration 
 
Genetic determinants of vitamin D status are presented in Table 3. After adjusting for sex, age, ethnicity, BMI, 
SEP, number of hours spent outdoors, quarter of sampling, vitamin D supplement consumption, recent sunny 
holiday and GOLD stage, and correcting for multiple comparison testing (Benjamini & Hochberg, FDR=0.05) 
none of the SNP investigated was found to associate with serum 25(OH)D concentration. 
 
3.4. Association between vitamin D status and clinical correlates of COPD severity 
 
After adjustment for potential environmental confounders, profound vitamin D deficiency was found to 
associate independently with reduced % predicted FEV1 (adjusted mean difference of -9.6% for those with a 
serum 25(OH)D concentration of <25 nmol/L vs. those with serum 25(OH)D concentration ≥75 nmol/L; 95% CI -
18.8 to -0.4%, Table 4, though the P value for trend across all 4 subgroups of vitamin D status was of 
borderline significance (P=0.060). Vitamin D status also inversely associated with % predicted FVC (adjusted 
mean difference of -12.5% for those with serum 25(OH)D concentration of <25 nmol/L vs. those with serum 
25(OH)D concentration ≥75 nmol/L; 95% CI -20.7 to -4.2%; P value for trend across all 4 categories of vitamin D 
status = 0.003, Table 5). We found no statistically significant association between vitamin D status and the 
other markers of COPD severity investigated, namely: FEV1:FVC (Table S1), quadriceps strength (Table S2), St. 
George’s respiratory questionnaire score (Table S3), daily inhaled corticosteroid dose (Table S4), percentage of 
eosinophils in sputum (Table S5), or percentage of neutrophils in sputum (Table S6).  
 
Multiple linear regression analysis revealed several other factors to independently associate with various 
clinical features of COPD. Higher % predicted FEV1 associated with higher BMI (Table 4, adjusted mean 
difference of 7.6% for those ≥25kg/m
2
 vs. <25kg/m
2
; 95% CI 2.4 to 12.8%; P=0.004), and with female sex (Table 
S4, adjusted mean difference of -6.1% lower for males; 95% CI -11.6 to -0.6; P=0.03). Higher FEV1:FVC 
associated with higher BMI (Table S2, adjusted mean difference of 17.0% for those ≥25kg/m
2
 vs. <25kg/m
2
; 
95% CI 9.0 to 26.0%; P<0.001), and with decreasing age (Table S1, adjusted mean difference of 10.0% lower in 
the 4
th
 vs. 1
st
 age quartile; 95% CI 0.81 to 1.00; P value for trend = 0.02). Lower % predicted FVC associated 
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with male sex (Table 5, adjusted mean difference of 11.1% lower for males; 95% CI -16.07 to -6.21; P<0.001). 
Diminished quadriceps strength associated with older age (Table S2, adjusted mean difference of 9.3 kg less 
for 4
th
 vs. 1
st
 age quartile; 95% CI -14.7 to -3.8; P value for trend <0.001) and non-smoking status (Table S2, 
adjusted mean difference of 4.7kg higher for smokers vs. non-smokers; 95% CI 0.1 to 8.5kg; P=0.02). Poorer 
respiratory quality of life, as indicated by lower St. George’s Respiratory Questionnaire scores, associated with 
older age (Table S3, adjusted mean difference of -8.7 points for 4
th
 vs. 1
st
 age quartile; 95% CI -15.6 to -1.8; P 
value for trend = 0.013). Finally, % eosinophils in sputum positively associated with % eosinophils in peripheral 
blood (Table S5, adjusted mean difference of 2.7% higher in those with blood eosinophils ≥3% vs. <3%; 95% CI 
1.4 to 5.0; P = 0.003). 
 
3.5. Association between genetic factors and clinical correlates of COPD severity 
 
Genetic determinants of clinical correlates of COPD severity are presented in Table S7 (FEV1), Table S8 (FVC), 
Table S9 (FEV1:FVC), and Table S10 (QS). After correcting for multiple comparisons testing none of the genetic 
factors which independently associated with markers of COPD severity as main effects, or by interaction with 
baseline vitamin D status, remained significant. 
 
 
4. Discussion 
 
To our knowledge this study represents the most comprehensive cross-sectional analysis of environmental and 
genetic determinants of serum 25(OH)D concentration and clinical correlates of disease severity in patients 
with COPD. It is also the first to explore the influence of vitamin D deficiency on induced sputum biomarkers of 
disease severity in this patient group.  
 
We found that vitamin D deficiency was present in the majority of participants, and that lower serum 25(OH)D 
concentrations were independently associated with increased BMI, lower SEP, lack of vitamin D supplement 
consumption, sampling in Winter or Spring and lack of recent sunny holidays abroad. Serum 25(OH)D 
concentration was positively correlated with % predicted FEV1 (9.6% difference in % predicted FEV1 
corresponded with a difference in mean raw FEV1 value of 0.21 litres; 95% CI -0.49 – 0.08; P=0.15, for <25 
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nmol/L vs. >75 nmol/L group) and % predicted FVC (12.5% difference in % predicted FVC corresponded with a 
difference in mean raw FVC value of: 0.28 litres; 95% CI -0.64 – 0.08; P=0.12, for <25 nmol/L vs. >75 nmol/L 
group), but not with any other measure of disease severity investigated. Genetic variation in the vitamin D 
pathway was not found to associate with vitamin D status or disease severity. 
 
The findings we present on environmental determinants of vitamin D status are in agreement with previous 
findings in the healthy UK population (26). The associations we observed between vitamin D status and indices 
of spirometric lung function, namely % predicted FEV1 and % predicted FVC, are also consistent with previous 
reports (3-7). Prospective studies with careful measurement of potential confounders are required to establish 
whether vitamin D deficiency is a cause or effect of reduced lung volumes, or whether this association is due 
to residual confounding. Our findings of no association between vitamin D status and FEV1:FVC, or quadriceps 
strength are in agreement with the majority of previous observational findings (4, 6, 9, 10), whilst the lack of 
association between vitamin D status and ICS dose we report is in contrast to a case-control study conducted 
in Norway which found a 5 nmol/L lower mean serum 25(OH)D concentration in COPD cases using ICS vs. those 
who were not (P=0.05) (8). However, the analysis conducted in this study was univariate, so factors which may 
have confounded the relationship between vitamin D status and ICS dose, such as sex, age, BMI and SEP, were 
not controlled for. 
 
4.1. Study strengths 
 
Our study has several strengths. We characterised our patients in a considerable level of detail which allowed 
us to investigate a wide range of potential genetic and environmental determinants of vitamin D status, and to 
control for a wide range of potential factors which may confound the relationship between vitamin D status 
and markers of COPD severity. Spirometry was performed using international guidelines and serum 25(OH)D 
concentrations were measured with the gold standard assay (LC-MS/MS) in a laboratory that participated in 
the international vitamin D external quality assurance scheme (www.deqas.org/). Our study population 
included COPD patients with a range of disease severity, who were recruited in both community and hospital 
settings and across all four seasons – all of which are factors that enhance the generalisibility of our results. 
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Finally, to our knowledge, this was the first study of COPD patients to investigate a cross-sectional relationship 
between vitamin D status and sputum biomarkers. 
 
4.2. Study limitations 
 
Our study also has some limitations. Due to the high prevalence of vitamin D deficiency in our cohort only a 
little over 10% of participants had a serum 25(OH)D concentration >75 nmol/L: we may therefore have been 
underpowered to detect associations between the highest serum concentrations of 25(OH)D and clinical 
correlates of COPD severity. Type 2 error as a result of limited power may also have been an issue in our 
analysis of quadriceps strength, which was conducted in a subset of 134 patients, and sputum markers of 
COPD severity, which was conducted in a subset of 44 patients, and it may have prevented us from detecting 
modest effects of genetic variation on vitamin D status and disease severity. 
 
In conclusion, our findings highlight a high prevalence of vitamin D deficiency in a UK population of COPD 
patients, which was independently associated with reduced % predicted FEV1 and % predicted FVC. Vitamin D 
deficiency was associated with classical environmental determinants as reported in healthy populations, but 
not with genetic variation in the vitamin D pathway. Our findings will help clinicians to identify COPD patients 
who are at particular risk of vitamin D deficiency, and allow correction of deficiency where appropriate – an 
intervention that has now been shown to reduce risk of COPD exacerbations in two clinical trials (11, 27). 
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Table.1 Participant Characteristics  
  N=278 
Sex, n (%) Female 109 (39.2) 
 Male 169 (60.8) 
Mean Age, yrs (range)   66.4 (40.8 -91.9) 
Mean BMI, kg/m2 (s.d.)  27.7 (6.8) 
Ethnicity, n (%) 1 White 262 (94.2) 
 Asian / Asian British 5 (1.8) 
 Black / Black British 2 (0.7) 
 Mixed 5 (1.8) 
Fitzpatrick Skin-type, n (%) 2 1 35 (12.8) 
 2 56 (20.5) 
 3 137 (50.2) 
 4 29 (10.6) 
 5  15 (5.5) 
 6  1 (0.4) 
Socio-economic Position, n (%) 3 1 81 (29.7) 
 2 24 (8.8) 
 3 42 (15.4) 
 4 62 (23.7) 
 5 64 (23.4) 
Time outdoors, hours/day (%) 4 >2hrs 130 (47.6) 
 ≤2hrs 143 (52.4) 
Daily vitamin D supplements, n (%) 5 Any 52 (19.3) 
 None 217 (80.7) 
Quarter of sampling, n (%) Q1 (Jan – Mar) 82 (29.5) 
 Q2 (Apr – Jun) 55 (19.8) 
 Q3 (Jul – Sep) 69 (24.8) 
 Q4 (Oct – Dec) 72 (25.9) 
Smoking status, n (%) Non-current 169 (60.8) 
 Current 109 (39.2) 
Mean alcohol, units/week (s.d.) 6  10.9 (18.3) 
Managed exclusively in primary care, n (%)  202 (72.7) 
Medication use Short-acting bronchodilator 203 (73.0) 
 Long-acting β agonist 30 (10.8) 
 Inhaled corticosteroid and long-acting β agonist 
combination 10 
140 (50.4) 
 Inhaled corticosteroid only 41 (14.7) 
 Tiotropium 98 (35.3) 
 Mean daily inhaled corticosteroid dose at entry in 
betamethasone equivalents, μg (s.d.) 11 
698.9 (723.7) 
Mean serum corrected calcium (s.d.) 7  2.25 (0.09) 
Recent sunny holiday, n (%) 8 Yes 16 (5.9) 
 No 257 (94.1) 
Tanning bed use in previous yr, n (%) 9 Yes 4 
 No 269 
GOLD Stage I 69 (24.8) 
 II 131 (47.1) 
 III 62 (22.3) 
 IV 16 (5.8) 
Mean serum PTH (s.d.)  5.9 (3.0) 
Serum PTH >6.8 pmol/L, n (%) Yes 68 (24.5) 
 No 210 (75.5) 
Serum 25(OH)D, nmol/L (%) ≥75 33 (11.9) 
 50 – 74.9 74 (26.6) 
 25 – 49.9 110 (39.6) 
 <25 61 (21.9) 
Mean serum 25(OH)D (s.d.)  45.3 (25.4) 
[1] Ethnicity not reported in n=4. Mixed ethnicity participants: n=3 ‘White and Black Caribbean’; n=1 ‘White and Black African’; n=1 ‘White and 
Asian’.  
[2] Fitzpatrick skin-type score not reported in n=5. Categories defined as:  1 = extremely fair skin; always burn, never tan, 2 = fair skin; always 
burn, sometimes tan, 3 = pale skin; sometimes burn, always tan, 4 = olive skin; rarely burn, always tan, 5 = moderately pigmented brown skin; 
never burn, always tan, 6 = markedly pigmented black skin; never burn, always tan.  
16 
 
[3] SEP not reported in n=5. Classes defined as: 1 = managerial, administrative and professional occupations, 2 = intermediate occupations, 3 = 
small employers and own account workers, 4 = lower supervisory and technical occupations, 5 = semi-routine and routine occupations, 6 = 
student, 7 = Never/Long-term (>5yrs) unemployed.  
[4] Time outdoors not reported in n=5.  
[5] Vitamin D supplementation consumption not reported in n=9.  
[6] Alcohol consumption not reported in n=13.  
[7] Corrected calcium not measured in n=5. 
[8] Recent sunny holiday not reported in n=5. Defined as a trip to any location within a latitude 51
o
 North/South of the equator, during the 
local sunny season, 2 months prior to blood draw, for a duration of ≥1 week.  
[9] Tanning bed use not reported in n=5.  
[10] Includes combinations of ICS/LABA and LABA.  
[11] 1µg betamethasone assumed equivalent to 1µg budesonide, 0.5 µg fluticasone dipropionate and 0.75 µg ciclesonide. 
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Table.2. Environmental determinants of serum 25-hydroxyvitamin D concentration in COPD patients 
  N Serum 25(OH)D, nmol/L  Univariate              
P value 1 
Multivariable model -   
Beta Coefficient (95% CI) 
P value 2 
   Mean (s.d.) Mean 
difference 
   
Sex Female 109 49.1 (29.2) referent 0.049 referent 0.52 
 Male 169 42.9 (22.3) -6.2  -2.1 (-8.6 to 4.4)  
Age quartiles 1 (40.8 – 60.3 yrs) 69 45.3 (27.3) referent 0.68 referent 0.84† 
 2 (60.5 – 65.3 yrs) 70 47.1 (23.8) +1.8  +1.5 (-6.9 to 9.9)  
 3 (65.3 – 72.3 yrs) 69 46.6 (28.3) +1.3  0.0 (-8.5 to 8.5)  
 4 (72.4 – 91.9 yrs) 70 42.3 (21.9) -3.0  -0.4 (-9.3 to 8.4)  
BMI, kg/m2 <25 109 48.9 (29.4) referent 0.058 referent 0.001 
 ≥25 169 43.0 (22.1) -5.9  -10.1 (-16.2 to -4.0)  
Ethnicity 3 White 262 45.9 (25.7) referent 0.29 referent 0.29 
 Other  12 37.9 (17.2) -8.0  -16.4 (-46.7 to 13.9)  
SEP 4 Higher 105 50.0 (28.0) referent 0.029 referent 0.037 
 Lower 168 43.1 (23.2) -6.9  -6.6 (-12.8 to -0.4)  
Time outdoors, hrs/day 5 >2 130 50.5 (27.7) referent 0.003 referent 0.069 
 ≤2 143  41.5 (22.2) -9.0  -5.5 (-11.5 to 0.4)  
Vitamin D supplements 6 Any 52 57.8 (27.8) referent <0.001 referent  <0.001 
None 217  42.8 (24.1) -15.0  -12.4 (-19.6 to -5.2)  
Quarter of sampling Q1 (Jan – Mar) 82 37.2 (23.4) -15.2 0.001 -14.0 (-22.3 to -5.7) 0.006† 
 Q2 (Apr – Jun) 55 43.7 (20.0) -8.7  -8.0 (-16.9 to 0.8)  
 Q3 (Jul – Sep) 69 52.4 (24.5) referent  referent  
 Q4 (Oct – Dec) 72 49.0 (29.5) -3.4  -3.0 (-11.2 to 5.2)  
Fitzpatrick skin-type 7 1,2 91 44.8 (24.7) -1.9 0.73 -4.0 (-10.4 to 2.4) 0.42† 
 3,4 166 46.7 (26.0) referent  referent  
 5,6 16 42.3 (22.6) -4.4  +7.2 (-19.7 to 34.0)  
Smoking status Non-current 169 45.4 (22.2) referent 0.97 referent 0.15 
 Current 109 45.3 (29.8) -0.1  -4.7 (-11.1 to 1.7)  
Alcohol consumption, units/wk 8 0 121 47.4 (26.4) referent 0.42 referent 0.49† 
1-20 98 44.1 (22.6) -3.3  -5.3 (-12.0 to 1.4)  
>20 46 42.4 (26.4) -5.0  -2.9 (-11.2 to 5.5)  
Recent sunny holiday 9 Yes 16 67.4 (36.0) referent <0.001 referent 0.002 
 No 257 44.4 (24.0) -23.0  -20.2 (-32.7 to -7.6)  
Tanning bed use, previous yr  Yes 4 90.8 (34.6) referent <0.001 *  
 No 269 45.1 (24.7) -45.7    
[1] Univariate method: Student’s T-test/One-way ANOVA.  
[2] Adjusted for all potential determinants of 25(OH)D concentration included in univariate analysis. 
[3] Ethnicity not reported in n=4.‘Other’ ethnicity defined as: n=5 Asian/Asian British, n=2 Black/Black British, n=5 mixed ethnicity. 
[4] SEP not reported in n=5. ‘Higher’ defined as classes: 1 (managerial, administrative and professional occupations) and 2 (intermediate 
occupations), ‘Lower’ defined as classes: 3 (small employers and own account workers), 4 (lower supervisory and technical occupations), and 5 
(semi-routine and routine occupations). 
[5] Time outdoors not reported in n=5. 
[6] Vitamin D supplementation consumption not reported in n=9. 
[7] Fitzpatrick skin-type score not reported in n=5. Categories defined as:  1 = extremely fair skin; always burn, never tan, 2 = fair skin; always 
burn, sometimes tan, 3 = pale skin; sometimes burn, always tan, 4 = olive skin; rarely burn, always tan, 5 = moderately pigmented brown skin; 
never burn, always tan, 6 = markedly pigmented black skin; never burn, always tan 
[8] Alcohol consumption not reported in n=13. 
[9] Recent sunny holiday not reported in n=5. Defined as a trip to any location within a latitude 51o North/South of the equator, during the local 
sunny season, 2 months prior to blood draw, for a duration of ≥1 week.†P value for trend. 
* Tanning bed use omitted from multivariable analysis due to <5 participants in ‘yes’ category. 
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Table.3. Genetic determinants of serum 25-hydroxyvitamin D concentration in COPD patients 
Gene SNP Genotype N 1 Serum 25(OH)D, nmol/L Multivariable model -   
Beta Coefficient (95% CI) 
P Value for 
trend 2 
    Mean (s.d.) Mean 
difference 
  
CYP24A1 
  
  
  
  
  
rs6013897 
  
  
TT 180 44.3 (25.5) referent referent 0.54 
AT 78 47.3 (25.2) +3.0 +3.3 (-3.1 to 9.8)  
AA 13 43.5 (21.1) -0.8 +4.5 (-9.8 to 18.7)  
rs2248137 
  
  
CC 96 46.4 (29.4) referent referent 0.49 
CG 144 44.0 (23.1) -2.4 +2.5 (-4.2 to 9.1)  
GG 33 45.0 (21.7) -1.6 +3.4 (-6.2 to 13.0)  
DBP 
  
  
  
  
  
  
  
  
  
  
  
  
rs16846876 
  
  
AA 124 47.2 (24.3) referent referent 0.41 
AT 126 43.3 (26.8) -3.9 -2.6 (-8.9 to 3.6)  
TT 23 42.2 (22.3) -5.0 -2.2 (-13.2 to 8.8)  
rs7041 
  
  
GG 65 50.3 (28.8) referent referent 0.010 
TG 147 44.0 (25.5) -6.3 -6.3 (-13.4 to 0.9)  
TT 57 40.9 (19.7) -9.4 -11.6 (-20.4 to -2.9)  
rs12512631 
  
  
TT 113 44.2 (23.4) referent referent 0.12 
CT 130 45.3 (26.6) +1.1 +0.2 (-6.2 to 6.6)  
CC 28 48.7 (26.0) +4.5 +8.2 (-2.2 to 18.5)  
rs4588 
  
  
CC 130 48.5 (26.1) referent referent 0.099 
CA 123 42.9 (25.4) -5.6 -5.1 (-11.2 to 1.1)  
AA 23 39.9 (20.3) -8.6 -9.2 (-20.1 to 1.7)  
rs2070741 
  
  
TT 237 44.7 (25.5) referent referent 0.84 
TG 31 49.8 (24.1) +5.1 +0.4 (-8.8 to 9.6)  
GG 3 53.3 (19.1) +8.6 -2.9 (-30.9 to 25.1)  
rs2298849 
  
  
AA 181 44.2 (24.5) referent referent 0.38 
AG 87 47.1 (27.5) +2.9 +2.5 (-3.8 to 8.9)  
GG 7 41.7 (18.1) -2.5 -8.0 (-25.8 to 9.8)  
CYP27B1 
  
  
rs4646536 
  
  
AA 111 44.0 (27.2) referent referent 0.65 
AG 128 45.7 (25.2) +1.7 +0.3 (-6.2 to 6.7)  
GG 29 47.6 (22.8) +3.6 +2.4 (-8.0 to 12.7)  
CYP2R1 
  
  
  
  
  
  
rs10500804 
  
  
TT 95 46.6 (28.6) referent referent 0.49 
GT 132 45.9 (24.7) -0.7 -2.6 (-9.2 to 4.1)  
GG 47 40.7 (21.1) -5.9 -3.0 (-11.6 to 5.5)  
rs2060793 
  
  
GG 95 42.9 (23.6) referent referent 0.99 
AG 129 48.1 (48.1) +5.2 +6.1 (-0.5 to 12.7)  
AA 49 42.6 (25.2) -0.3 0.0 (-8.6 to 8.6)  
rs10766197 
  
  
GG 79 45.8 (27.8) referent referent 0.53 
AG 132 46.0 (24.1) +0.2 -2.5 (-9.4 to 4.4)  
AA 57 41.9 (27.8) -3.9 -2.6 (-10.8 to 5.6)  
DHCR7 
  
  
  
  
rs12785878 
  
  
TT 171 45.5 (25.7) referent referent 0.33 
GT 87 45.4 (25.8) -0.1 -1.6 (-7.9 to 4.7)  
GG 15 39.3 (17.9) -6.2 -7.5 (-22.4 to 7.5)  
rs3829251 
  
  
GG 210 45.8 (25.6) referent referent 0.22 
AG 54 45.1 (25.1) -0.7 -1.7 (-8.8 to 5.4)  
AA 7 31.9 (10.1) -13.9 -12.0 (-31.5 to 7.4)  
VDR 
  
   
rs10783219 
  
  
AA 106 44.6 (24.0) referent referent 0.026 
AT 126 46.6 (25.5) +2.0 -3.4 (-9.8 to 3.1)  
TT 33 37.8 (23.5) -6.8 -10.9 (-20.4 to -1.3)  
[1] Genotyping not conducted in n=1. 
[2]Adjusted for sex, age, BMI, ethnicity, SEP, hours outdoors, vitamin D supplement consumption, season of blood draw, 
Fitzpatrick skin-type, smoking status, alcohol consumption, recent sunny holiday, tanning bed use, and GOLD stage, and 
corrected for multiple comparisons testing, using the Benjamini & Hochberg method with a 5% false discovery rate. 
Abbreviations: DBP: vitamin D binding protein, CYP2R1: cytochrome P450-2R1, CYP24A1: cytochrome P450-24A1, CYP27B1: 
cytochrome P450-27B1, DHCR7: 7-dehydrocholesterol reductase, VDR: vitamin D receptor, SNP: single nucleotide 
polymorphism, s.d.: standard deviation, CI: confidence interval. 
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Table 4. Determinants of % predicted Forced Expiratory Volume in 1 second (FEV1) 
   
N 
Mean % 
predicted FEV1 
(SD) 
Univariate              
P value 1 
Multivariable model – 
beta coefficient (95% CI) 
P value 2  
Sex Female 109 68.6 (20.2) 0.001 referent 0.029  
 Male 169 60.4 (20.2)  -6.1 (-11.6 to -0.6)  
Age quartiles 1 (40.8 – 60.3 yrs) 69 66.8 (19.8) 0.24 referent 0.085† 
 2 (60.5 – 65.3 yrs) 70 65.3 (19.2)  -3.0 (-10.3 to 4.2)  
 3 (65.3 – 72.3 yrs) 69 61.6 (22.5)  -7.2 (-14.6 to 0.2)  
 4 (72.4 – 91.9 yrs) 70 60.7 (20.3)  -5.5 (-13.0 to 1.9)  
BMI, kg/m2 <25 109 59.3 (20.8) 0.005 referent 0.004 
 ≥25 169 66.4 (19.9)  +7.6 (2.4 to 12.8)  
Ethnicity 3 White 262 63.7 (20.7) 0.52 referent 0.57 
 Other  12 59.8 (13.4)  -3.6 (-16.0 to 8.9)  
SEP 4 Higher 105 68.0 (19.7) 0.007 referent 0.089 
 Lower 168 61.1 (20.6)  -4.6 (-10.0 to 0.7)  
Smoking status Non-current 169 63.3 (21.4) 0.75 referent 0.89 
 Current 109 64.1 (19.1)  +0.4 (-5.1 to 5.8)  
Alcohol consumption, units/wk 5 0 121 63.2 (21.0) 0.76 referent 0.26† 
 1-20 98 65.2 (18.9)  +3.2 (-2.4 to 8.8)  
 >20 46 64.8 (22.3)  +4.1 (-3.1 to 11.3)  
Influenza vaccination Yes 255 63.7 (20.6) 0.91 referent 0.71 
No 23 63.1 (19.9)  -1.9 (-11.7 to 7.9)  
Pneumonia vaccination  Yes 179 62.9 (20.1) 0.45 referent 0.35 
No 99 64.9 (21.4)  +2.6 (-2.9 to 8.2)  
Serum 25(OH)D, nmol/L ≥75 33  69.3 (19.4) 0.16 referent 0.060† 
74.9 – 50 74  63.6 (20.0)  -5.8 (-14.4 to 2.8)  
49.9 – 25 110 64.3 (20.2)  -4.0 (-12.2 to 4.3)  
<25 61 59.4 (21.9)  -9.6 (-18.8 to -0.4)  
[1] Univariate analysis method:Students T-test / One-way ANOVA test.  
[2] Adjusted for all potential determinants of FEV1investigated in univariate analysis. 
[3] Ethnicity not reported in n=4.‘Other’ ethnicity defined as: n=5 Asian/Asian British, n=2 Black/Black British, n=5 mixed ethnicity. 
[4] SEP not reported in n=5. ‘Higher’ defined as classes: 1 (managerial, administrative and professional occupations) and 2 (intermediate 
occupations), ‘Lower’ defined as classes: 3 (small employers and own account workers), 4 (lower supervisory and technical occupations), 
and 5 (semi-routine and routine occupations). 
[5] Alcohol consumption not reported in n=13. 
†P value for trend 
Definitions: 25(OH)D: 25-hydroxyvitamin D, BMI: Body mass index, SEP: Socio-economic position, CI: Confidence interval, SD: Standard 
deviation, nmol/L: Nanomoles per litre, SEP: Socio-economic position. 
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Table 5. Determinants of % predicted Forced Vital Capacity (FVC) 
   
N 
Mean % 
predicted FVC 
(SD) 
Univariate              
P value 1 
Multivariable model – 
beta coefficient (95% CI) 
P value 2  
Sex Female 109 104.0 (19.0) <0.001 referent <0.001  
 Male 169 92.2 (17.8)  -11.14 (-16.07 to -6.21)  
Age quartiles 1 (40.8 – 60.3 yrs) 69 98.6 (19.3) 0.69 referent 0.52† 
 2 (60.5 – 65.3 yrs) 70 97.8 (18.6)  -0.77 (-7.29 to 5.75)  
 3 (65.3 – 72.3 yrs) 69 95.1 (18.7)  -3.57 (-10.21 to 3.08)  
 4 (72.4 – 91.9 yrs) 70 95.9 (20.1)  -1.36 (-8.05 to 5.32)  
BMI, kg/m2 <25 109 98.3 (19.7) 0.29 referent 0.40 
 ≥25 169 95.8 (18.8)  -2.00 (-6.64 to 2.64)  
Ethnicity 3 White 262 97.5 (19.3) 0.009 referent 0.045 
 Other  12 82.7 (9.8)  -11.41 (-22.58 to -0.24)  
SEP 4 Higher 105 101.5 (19.3) 0.002 referent 0.12 
 Lower 168 94.3 (18.6)  -3.80 (-8.59 to 0.98)  
Smoking status Non-current 169 96.6 (19.4) 0.78 referent 0.60 
 Current 109 97.2 (18.8)  -1.29 (-6.19 to 3.61)  
Alcohol consumption, units/wk 5 0 121 97.2 (19.8) 0.89 referent 0.31† 
 1-20 98 98.1 (17.5)  +3.45 (-1.56 to 8.46)  
 >20 46 96.7 (20.0)  +3.30 (-3.14 to 9.73)  
Influenza vaccination Yes 255 96.8 (18.8) 0.94 referent 0.97 
No 23 96.5 (23.5)  -0.19 (-8.97 to 8.59)  
Pneumonia vaccination  Yes 179 97.1 (17.0) 0.75 referent >0.99 
No 99 96.3 (22.7)  +0.02 (-4.95 to 4.98)  
Serum 25(OH)D, nmol/L ≥75 33  107.4 (18.4) 0.002 referent 0.003† 
74.9 – 50 74  98.2 (18.0)  -7.07 (-14.80 to 0.66)  
49.9 – 25 110 95.4 (18.9)  -8.00 (-15.39 to -0.59)  
<25 61 92.0 (19.5)  -12.46 (-20.70 to -4.21)  
[1] Univariate analysis method: Students T-test / One-way ANOVA test.  
[2] Adjusted for all potential determinants of FVC investigated in univariate analysis. 
[3] Ethnicity not reported in n=4, ‘Other’ ethnicity defined as: n=5 Asian/Asian British, n=2 Black/Black British, n=5 mixed ethnicity. 
[4] SEP not reported in n=5. ‘Higher’ defined as classes: 1 (managerial, administrative and professional occupations) and 2 (intermediate 
occupations), ‘Lower’ defined as classes: 3 (small employers and own account workers), 4 (lower supervisory and technical occupations), 
and 5 (semi-routine and routine occupations). 
[5] Alcohol consumption not reported in n=13. 
†P value for trend 
Definitions: 25(OH)D: 25-hydroxyvitamin D, BMI: Body mass index, SEP: Socio-economic position, CI: Confidence interval, SD: Standard 
deviation, nmol/L: Nanomoles per litre, SEP: Socio-economic position. 
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